Science and Technology

Our Strategy

Portfolio expansion is a strategic priority for our Science and Technology organization. We are committed to both developing new medicines and generating relevant clinical, health economic and outcomes data that extends the durability of our in-line brands. Mallinckrodt is building on its legacy expertise, especially in formulation technologies and the challenging management of controlled substances, and expanding and deepening our clinical development capabilities. We currently have over two dozen programs, in various stages of development, across our key areas of focus- Specialty Generics, Acute and Critical Care, and Autoimmune and Rare Diseases.

To read more, please click to go to the global site ›